Management of Cilostazol-Associated Rash
Discontinue cilostazol immediately if a rash develops, as this represents a potential hypersensitivity reaction that could progress to more severe manifestations.
Immediate Action
When a patient on cilostazol presents with a rash, stop the medication immediately. The FDA label explicitly contraindicates cilostazol in patients with "known or suspected hypersensitivity to any of its components" 1. While rash is not among the most commonly reported side effects (which include headache, diarrhea, abnormal stools, palpitations, and dizziness) 2, any cutaneous reaction warrants drug cessation given the potential for progression to serious hypersensitivity syndromes.
Assessment of Severity
Evaluate the rash characteristics to determine if this is:
- Simple cutaneous reaction: Isolated rash, itching, or flushing without systemic symptoms
- Systemic hypersensitivity: Fever >38.4°C, eosinophilia, lymphadenopathy, or internal organ involvement (DRESS syndrome pattern) 3
- Severe reaction: Urticaria, angioedema, mucosal involvement, or signs of anaphylaxis
Check complete blood count with differential looking for eosinophilia, and assess liver and kidney function if systemic symptoms are present 4.
Treatment Approach
For isolated cutaneous reactions:
- Discontinue cilostazol permanently
- Administer antihistamines for symptomatic relief
- Monitor for 2 weeks to ensure resolution 5
For systemic hypersensitivity reactions:
- Discontinue cilostazol immediately
- Initiate systemic corticosteroids (though evidence for benefit in drug hypersensitivity remains controversial) 3
- Provide supportive care and monitor organ function
- Consider hospitalization if severe
Alternative Antiplatelet Strategy
Since cilostazol is indicated for intermittent claudication in peripheral arterial disease 6, 7, 1, you must provide alternative management:
First-line alternative: Implement supervised exercise training (30-45 minutes, 3 times weekly for minimum 12 weeks) as this is Class I recommendation with Level A evidence 7.
Pharmacologic alternative: Consider pentoxifylline 400 mg three times daily as second-line therapy, though recognize its clinical effectiveness is marginal (Class IIb recommendation) 6, 7, 2, 6.
Do not rechallenge with cilostazol after a hypersensitivity reaction. Unlike some monoclonal antibodies where graded rechallenge protocols exist 4, there is no established desensitization protocol for cilostazol, and the risk-benefit ratio does not favor rechallenge given available alternatives.
Key Pitfalls to Avoid
- Do not continue cilostazol while "monitoring" the rash—this risks progression to severe hypersensitivity
- Do not assume all rashes are benign—cilostazol can cause serious adverse reactions affecting multiple organ systems 8
- Do not forget the black box warning—while focused on heart failure contraindication 2, 1, this underscores that cilostazol carries significant risks requiring vigilant monitoring
- Do not leave the patient without a treatment plan—supervised exercise remains highly effective and should be prescribed immediately 7
The evidence base specifically addressing cilostazol-induced rash is limited in the provided guidelines, which focus primarily on efficacy and cardiovascular safety. However, the general principles of drug hypersensitivity management 3 combined with the FDA contraindication for hypersensitivity 1 make permanent discontinuation the only appropriate course of action.